Evidence map›Paper›PMID 41260656›Full record

ArticleInternal medicine (Tokyo, Japan)2026

Hereditary Neuropathy with Liability to Pressure Palsies Unmasked by Polatuzumab Vedotin-containing Chemotherapy.

Takeru Kawanami, Masaaki Yoshikawa, Yuta Goto, Rintaro Hirahara, Yuki Hoshino, Chika Shichijo, Toshihiro Ide, Kohei Suzuyama, Haruki Koike

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Takeru KawanamiDepartment of Neurology, Saga University, Japan.
Masaaki YoshikawaDepartment of Neurology, Saga University, Japan.
Yuta GotoDepartment of Neurology, Saga University, Japan.
Rintaro HiraharaDepartment of Neurology, Saga University, Japan.
Yuki HoshinoDepartment of Neurology, Saga University, Japan.
Chika ShichijoDepartment of Neurology, Saga University, Japan.
Toshihiro IdeDepartment of Neurology, Saga University, Japan.
Kohei SuzuyamaDepartment of Neurology, Saga University, Japan.
Haruki KoikeDepartment of Neurology, Saga University, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report the case of a 49-year-old man with hereditary neuropathy with liability to pressure palsies unmasked by polatuzumab vedotin-containing chemotherapy. Neuropathic symptoms were predominant in areas surrounding the right and left ulnar nerves after the first course of chemotherapy. However, they progressed in a stepwise manner, involving other limb regions, after the second and third courses. Nerve conduction studies revealed demyelinating neuropathy conspicuous at the compression sites, and fluorescence in situ hybridization showed deletion of the PMP22 gene. This case underscores the importance of considering the development or exacerbation of hereditary neuropathies including hereditary neuropathy with liability to pressure palsies in patients receiving polatuzumab vedotin.

Indexed as

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsArthrogryposisHereditary Sensory and Motor NeuropathyImmunoconjugatesHumansMaleMiddle AgedMyelin ProteinsNerve Conduction StudiesAntibodies, Monoclonal, HumanizedImmunoconjugatesMyelin ProteinsPMP22 protein, humanchemotherapydemyelinating neuropathyelectrophysiologyhereditary neuropathy with liability to pressure palsiespolatuzumab vedotin

Identifiers

PMID41260656
PMCPMC13423779

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.